Saturday 17 October 2026
Export PASG’s income statement to Excel — free account
Passage Bio, Inc.
PASG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.6% and free cash flow fell 59.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.48
0.12
−3.33%
Follow PASG
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.07 | 4.07 | 7.22 | 10.74 | 11.02 | 14.98 | 45.04 | 108.79 | — |
Net Debt/EBITDA |
0.96 | 1.11 | 1.07 | 1.42 | 1.74 | 2.73 | 4.29 | 2.46 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.69 | 0.74 | 0.77 | 0.87 | 0.68 | 0.72 | 0.87 | 1.45 | — |
Capex/Depreciation |
1.37 | (0.02) | (0.09) | (1.18) | (5.93) | (1.15) | (12.63) | — | — |
| (113.78%) | (75.07%) | (65.29%) | (52.35%) | (59.48%) | (90.34%) | 133.38% | 37.32% | — | |
| (55.28%) | (51.21%) | (51.80%) | (45.48%) | (54.28%) | (44.31%) | (43.04%) | (76.33%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | (735.76%) | (4,024.99%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(158.14%) | (94.16%) | (87.30%) | (67.65%) | (58.05%) | (37.56%) | (27.97%) | (38.56%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(9.56) | (15.59) | (28.65) | (45.37) | (57.18) | (42.56) | (196.36) | (0.41) | — |
Cash per Share |
14.59 | 24.93 | 41.76 | 69.67 | 118.39 | 157.87 | 750.11 | 0.54 | — |
Shareholders Equity per Share |
5.91 | 19.90 | 40.66 | 73.99 | 119.47 | 157.82 | (265.59) | (0.27) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
5.91 | 19.90 | 40.66 | 73.99 | 119.47 | 157.82 | (265.59) | (0.27) | — |
Free Cash Flow |
(30.34) | (47.99) | (78.41) | (123.48) | (152.52) | (82.17) | (41.59) | (18.57) | — |
Working Capital |
24.68 | 59.45 | 101.62 | 178.69 | 295.57 | 296.01 | 162.09 | 33.09 | — |
Capital Expenditures |
1.17 | (0.03) | (0.15) | (5.27) | (25.64) | (1.65) | (1.69) | (2.54) | — |
Net Current Asset Value |
4.24 | 37.66 | 78.70 | 154.86 | 288.65 | 293.89 | (69.09) | 30.88 | — |
| Other line items | |||||||||
Quick Ratio |
2.01 | 3.96 | 6.99 | 10.33 | 10.70 | 14.40 | 43.16 | 80.98 | — |
Depreciation/Fixed assets |
0.21 | 0.17 | 0.11 | 0.20 | 0.18 | 0.51 | 0.12 | 0.00 | — |
Cash ROIC |
(46.63%) | (34.77%) | (34.76%) | (31.58%) | (24.04%) | (13.48%) | (40.53%) | (146.34%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(9.93) | (15.58) | (28.59) | (43.44) | (47.57) | (41.70) | (188.37) | (0.41) | — |
Capex per Share |
0.37 | (0.01) | (0.05) | (1.94) | (9.61) | (0.85) | (7.99) | 0.00 | — |
Average Payables |
0.93 | 1.02 | 2.68 | 6.76 | 7.36 | 2.95 | 0.42 | 0.42 | — |
Average Assets |
82.35 | 126.48 | 197.05 | 299.31 | 341.54 | 253.31 | 106.04 | 16.73 | — |
Average Common Equity |
40.01 | 86.27 | 156.32 | 260.01 | 311.69 | 124.23 | (34.21) | (34.21) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates